Trial · NCT04720261
Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP
NCT04720261, Phase 2, Terminated, University Hospital, Rouen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP. Trials, record NCT04720261. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04720261
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP
- NCT number
- NCT04720261
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 58 participants, actual
- Lead sponsor
- University Hospital, Rouen
- Conditions
- Thrombotic Thrombocytopenic Purpura, Acquired
- Interventions
- Caplacizumab
- First posted
- 2021-01-22
- Last updated
- 2026-02-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To evaluate the feasibility of a personalized caplacizumab regimen in aTTP based on ADAMTS13 activity monitoring assessed by a composite criteria including mortality, refractoriness and/or exacerbation at 30 days post-PE treatment | 30 days post-PE treatment | composite endpoint defined by the occurrence of at least one the following events during the 30 days post-PE treatment: death, refractoriness or exacerbation. |
| Secondary | Response to treatment (platelet count recovery) | 30 days post-PE treatment | to platelet count recovery (as defined by a platelet count ≥ 150 G/L with a subsequent interruption of daily PE within 5 days) |
| Secondary | Durable remission achievement | 90 days post-PE treatment | Occurrence of durable remission achievement (platelet count ≥ 150 G/L for ≥ 30 consecutive days following PE interruption); |
| Secondary | Mortality at D90 post-PE treatment | 90 days post-PE treatment | Occurrence of death within 90 days post-PE treatment |
| Secondary | Refractoriness at D30 post-PE treatment | Day 30 post-PE treatment | Occurrence of refractoriness at D30 post-PE treatment; |
| Secondary | Exacerbation at D30 post-PE treatment | Day 30 post-PE treatment | Occurrence of exacerbations at D30 post-PE treatment |
| Secondary | Duration of plasma exchange (PE) treatment and the associated plasma volumes | 30 days | Duration of daily PE with the corresponding plasma volume |
| Secondary | Duration of plasma exchange (PE) treatment and the associated plasma | 30 days | Total number of PE and the corresponding plasma volume during the full study drug treatment period |
| Secondary | Occurrence of neurological sequelae treatment | Day 90 post-PE treatment | Neurological assessment based on Rankin score |
| Secondary | Evaluate the Quality of life | Day 90 post-PE treatment | Quality of life based on global post-traumatic score (PCL-S SCALE) at baseline, D90 post-PE treatment |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04720261
GET https://conductscience.org/api/trials/v1/NCT04720261/registered